[1]汤建林,李玉莹,高柳艳,等.甲状腺功能亢进症治疗方法的比较和选择[J].国际放射医学核医学杂志,2009,33(3):175-178.[doi:10.3760/cma.j.issn.1673-4114.2009.03.012]
　TANG Jian-lin,LI Yu-ying,GAO Liu-yan,et al.The methods and options of the treatment for hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(3):175-178.[doi:10.3760/cma.j.issn.1673-4114.2009.03.012]
点击复制

甲状腺功能亢进症治疗方法的比较和选择(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
33
期数:
2009年第3期
页码:
175-178
栏目:
核素治疗
出版日期:
1900-01-01

文章信息/Info

Title:
The methods and options of the treatment for hyperthyroidism
作者:
汤建林;  李玉莹;  高柳艳;  唐秀萍;  胡红永
大理白族自治州人民医院核医学科, 云南大理 671000
Author(s):
TANG Jian-lin;  LI Yu-ying;  GAO Liu-yan;  TANG Xiu-ping;  HU Hong-yong
Department of Nuclear Medicine, Indirected Affiliated Hospital of the Dali College, The People’s Hospital of the Dali Autonomous Prefeture, Yunnan Dali 671000, China
关键词:
甲状腺功能亢进症; 抗甲状腺药; 外科手术; 碘放射性同位素; 近距离放射疗法
Keywords:
Hyperthyroidism; Graves disease; Antithyroid agents; Surgical procedures; operative; Iodine radioisotopes; Brachytherapy
DOI:
10.3760/cma.j.issn.1673-4114.2009.03.012
摘要:
甲状腺功能亢进症(甲亢)是内分泌疾病中的常见多发病,抗甲状腺药物、外科手术和放射性碘治疗均为目前公认的治疗甲亢的有效方法。通过多年的临床实践和大量的分析研究,对上述三种治疗方法各自特点的认识进一步加深,在选择甲亢治疗方法的倾向方面也有了新的变化。众多学者在对三种治疗方法进行比较和评价后认为,在没有更好的生理学治疗方法产生之前,放射性碘治疗将保持其独特的地位,有成为甲亢首选疗法的趋势。
Abstract:
Hyperthyroidism is a frequently-occurring endocrine disease. Aantithyroid drugs, surgery and radioactive iodine therapy are currently accepted and effective methods of treatment for hyperthyroidism. Years of clinical practices and a lot of researches on each of the three treatment methods to further deepen the understanding of the characteristics, the choice of treatment for hyperthyroidism tend to have a new change. After comparing and evaluating the three treatments for hyperthyroidism, most scholars believe that radioactive iodine therapy to treat hyperthyroidism will maintain its unique position before the physiological treatment for hyperthyroidism is uncertainly discoveried in the future.

参考文献/References:

[1] 邢家骝.131碘治疗甲状腺疾病.北京:人民卫生出版社,2002.152-176.
[2] 高妍.应用基础研究指导临床实践,提高Graves病的长期缓解率.中华内分泌代谢杂志,1995,11(3):131-132.
[3] 医学会内分泌学分会《中目甲状腺疾病诊治指南》编写组.中国甲状腺疾病诊治指南-甲状腺功能亢进症.中华内科杂志,2007,46(10):876-882.
[4] 高妍.Graves病诊治中的几个问题.中华内分泌代谢杂志,2001,17(4):193-194.
[5] 田硕涵,周颖.抗甲状腺药的进展与应用评价.中国医院用药评价与分析,2008,8(6):410-411.
[6] 杨春明.甲状腺功能亢进的外科治疗.中国普通外科杂志,2007,16(1):4-6.
[7] Rudberg C, Johansson H, Akerstr? m G, et al. Graves’ disease in children and adolescents. Late results of surgical treatment. Eur J Endocrinol, 1996, 134(6):710-715.
[8] 匡安仁.内分泌疾病的治疗//张永学.核医学.北京:人民卫生出版社,2005:353-358.
[9] Ron E, Doody MM, Becker DV, et al. Cancer mortality following treatment for adult hyperthyroidism. JAMA, 1998, 280(4):347-355.
[10] 邢家骝.131碘治疗甲状腺疾病.北京:人民卫生出版社,2002:145-151.
[11] 卢倜章.甲状腺功能亢进症//马寄晓,刘秀杰.实用临床医学.2版.北京:原子能出版社,2002,471-482.
[12] 邢家骝.131Ⅰ治疗甲状腺功能亢进症对性腺的影响.中华内分泌代谢杂志,2007,23(6):481-483.
[13] [No authors listed]. Summary of current radiation close estimates to humans from 123I, 124I, 125I,126I,130I,131I, and 132I as sodium iodide. J Nucl Med, 1975, 16(9):857-860.
[14] ICRP-53. Radioation dose to patients from radiopharmaceuticals. Ann ICRP, 1987, 18(1-4):1-29.
[15] Stabin MG, Stubbs JB, Toohey RE. Radioation dose estimates for radiopharmaceuticals. ORISE Document, April 30,1996,available at www.orise.orau.gov/reacts.
[16] 邢家骝.131碘治疗甲状腺疾病.北京:人民卫生出版社,2002:50-52.
[17] Berg GE, Michanek AM, Holmberg EC, et al. Iodine-131 treatment of hyperthyroidism:significance deflective half-life measurements. J Nucl Med, 1996,37(2):228-232.
[18] Rivkees SA, Sklar C, Frecmark M. Clinical review 99:The management of Graves’ disease in chihtren, with special emphasis on radioiodine treatment. J Clin Endocrinol Metab, 1998, 83(11):3767-3776.
[19] 陈敏,周翔天,盛文,等.甲状腺相关性眼病研究治疗新进展.国际眼科杂志,2006,6(4):875-878.
[20] Read CH Jr, Tansey M J, Menda Y. A 36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves’ patients. J Clin Endoerinol Metab, 2004, 89(9):4229-4233.
[21] 陈文贤,颜兵.抗甲状腺药物和131碘治疗甲亢的医疗成本分析.中国卫生事业管理,1999,15(6):302-305.
[22] Singer PA, Cooper DS, Levy EC, et al. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of Care Committee, American Thyroid Association. JAMA, 1995, 273(10):808-812.
[23] Arbelle JE, Porath A. Practice guidelines for the detection and management of thyroid dysfunction, A comparative review of the recommendations. Clin Endocrinol, 1999, 51(1):11-18.
[24] Wartoisky L. Radiniodine therapy for Graves disease:ease selection and restrictions recommended to patients in North America. Thyroid, 1997, 7(2):213-216.

相似文献/References:

[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
　Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
　Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[3]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
　Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[4]张丽花,蒋宁一.131I治疗Graves甲亢合并肝功能损害或血细胞减少的优势与风险[J].国际放射医学核医学杂志,2015,39(6):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
　Zhang Lihua,Jiang Ningyi.The advantage and risk of 131I treatment in hyperthyroidism combined with liver injury or blood cell reduction[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
[5]杨宝军.131I治疗甲亢合并特发性血小板减少性紫癜一例[J].国际放射医学核医学杂志,2015,39(6):511.[doi:10.3760/cma.j.issn.1673-4114.2015.06.017]
[6]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
　Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[7]苑丽丽,张阳,樊琳琳,等.甲巯咪唑致粒细胞缺乏症2例[J].国际放射医学核医学杂志,2014,38(5):347.[doi:10.3760/cma.j.issn.1673-4114.2014.05.016]
[8]张瑞国,秦岚,张又萍,等.初诊Graves甲亢合并肝损害及其影响因素的临床分析[J].国际放射医学核医学杂志,2013,37(5):283.[doi:10.3760/cma.j.issn.1673-4114.2013.05.008]
　ZHANG Rui-guo,QIN Lan,ZHANG You-ping,et al.Clinical study of hepatic dysfunction and its correlative factors in newly diagnosed patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):283.[doi:10.3760/cma.j.issn.1673-4114.2013.05.008]
[9]黄春玲,查金顺,蒋婷吟.甲状腺功能亢进症患者血浆中TNF-α1和IL-2水平的临床分析[J].国际放射医学核医学杂志,2012,36(2):92.[doi:10.3760/cma.j.issn.1673-4114.2012.02.008]
　HUANG Chunling,ZHA Jin-shun,JIANG Ting-yin.The clinical analysis of the TNF-α1 and IL-2 levels in patients with hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(3):92.[doi:10.3760/cma.j.issn.1673-4114.2012.02.008]
[10]王澎,谭建.不同药物影响Graves病131Ⅰ治疗效果的研究进展[J].国际放射医学核医学杂志,2011,35(1):9.[doi:10.3760/cma.j.issn.1673-4114.2011.01.003]
　WANG Peng,TAN Jian.Advance of study on the influence of different drugs on the efficacy of 131I treatment for Graves’ disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(3):9.[doi:10.3760/cma.j.issn.1673-4114.2011.01.003]
[11]孟召伟,谭建.解读美国甲状腺协会和临床内分泌医师协会2011年甲亢诊治指南[J].国际放射医学核医学杂志,2011,35(4):193.[doi:10.3760/cma.j.issn.1673-4114.2011.04.001]
　MENG Zhao-wei,TAN Jian.Reading and analysis on management guidelines for hyperthyroidism published in 2011 by American Thyroid Association and American Association of Clinical Endocrinologists[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(3):193.[doi:10.3760/cma.j.issn.1673-4114.2011.04.001]
[12]王春梅,王雪梅.131I治疗甲亢的现状和研究进展[J].国际放射医学核医学杂志,2010,34(1):31.[doi:10.3760/cma.j.issn.1673-4114.2010.01.008]
　WANG Chun-mei,WANG Xue-mei.The development and current status of 131I treatment for hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(3):31.[doi:10.3760/cma.j.issn.1673-4114.2010.01.008]
[13]潘香颖,李慧贞.甲状腺功能亢进症伴肝功能受损的131I治疗疗效[J].国际放射医学核医学杂志,2009,33(3):179.[doi:10.3760/cma.j.issn.1673-4114.2009.03.013]
[14]苏莉,陈璟,赵明.131I治疗男性甲状腺亢进症周期性麻痹的临床观察:与抗甲状腺药物治疗比较[J].国际放射医学核医学杂志,2007,31(6):366.
　SU Li,CHEN Jing,ZHAO Ming.Clinical evaluation of the treatment in male patient with thyrotoxic periodic paralysis: 131I treatment compared with antithyroid drug therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(3):366.

备注/Memo

备注/Memo:
收稿日期:2008-12-17
通讯作者:汤建林,E-mail:tjl128@163.com
更新日期/Last Update: 1900-01-01